Featured Research

from universities, journals, and other organizations

Urinary infections steal from hosts' defense arsenals

Date:
July 8, 2012
Source:
Washington University in St. Louis
Summary:
Humans have known for centuries that copper is a potent weapon against infection. New research shows that the bacteria that cause serious urinary tract infections “know” this, too, and steal copper to prevent the metal from being used against them.

An immune cell called a neutrophil (shown in light blue) attacks bacteria that cause urinary tract infections. Scientists have discovered that the bacteria can steal copper -- a naturally occurring anti-microbial -- from the host to prevent the metal from being used to fight infection.
Credit: Chia Hung, PhD

Humans have known for centuries that copper is a potent weapon against infection. New research shows that the bacteria that cause serious urinary tract infections "know" this, too, and steal copper to prevent the metal from being used against them.

Blocking this thievery with a drug may significantly improve patients' chances of fighting off infections, according to researchers at Washington University School of Medicine in St. Louis. The findings appear online July 8 in Nature Chemical Biology.

In the United States alone, annual treatment costs for urinary tract infections are estimated to run as high as $1.6 billion. Most urinary tract infections are caused by Escherichia coli (E. coli).

"While some patients are able to clear these infections without issue, in others the infection persists or recurs despite antibiotic therapy," says senior author Jeff Henderson, MD, PhD, assistant professor of medicine and of molecular microbiology. "In some cases, the infection spreads to the kidney or the blood and becomes life-threatening. We've been investigating what's different about the bacteria that cause these more troublesome infections."

Scientists have known for years that E. coli makes a molecule called yersiniabactin that takes iron from host cells. The bacteria need the iron to grow and reproduce. In earlier research, Henderson found that the E. coli that cause serious infections are more likely to make yersiniabactin. This finding and the fact that E. coli already produce another molecule that steals iron led Henderson and Kaveri Chaturvedi, a student in his laboratory, to suspect that the bacterium might be using yersiniabactin for other purposes.

To test the theory, the researchers put yersiniabactin in urine samples from healthy patients. They found the molecule bound iron as expected but also picked up copper. Next, they conducted the same analysis in samples from patients with urinary tract infections who were treated at the University of Washington in Seattle.

"We found copper bound to yersiniabactin in nearly every patient whose bacteria made the molecule," Henderson says. "Yersiniabactin was often bound to copper more than it was to iron."

When researchers put E. coli in the same test tube with copper, the bacteria that made yersiniabactin were more likely to survive.

Copper's microbe-fighting properties were recognized long before scientists had described the microbes that cause infection. Ancient Greeks and Egyptians knew that treating wounds with copper improved the healing process.

Modern researchers have two explanations for copper's anti-microbial effects: the metal can stimulate production of other chemically reactive molecules that damage bacteria; and it is also directly toxic to the bacteria.

Henderson, who treats patients with urinary tract infections at Barnes-Jewish Hospital, is currently studying whether the presence or absence of yersiniabactin can help physicians assess an infection's chances of becoming more serious.

He and his colleagues are also looking at other disease-causing bacteria that make yersiniabactin to see if they use it in a fashion similar to the E. coli that cause urinary tract infections.


Story Source:

The above story is based on materials provided by Washington University in St. Louis. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kaveri S Chaturvedi, Chia S Hung, Jan R Crowley, Ann E Stapleton, Jeffrey P Henderson. The siderophore yersiniabactin binds copper to protect pathogens during infection. Nature Chemical Biology, 2012; DOI: 10.1038/nchembio.1020

Cite This Page:

Washington University in St. Louis. "Urinary infections steal from hosts' defense arsenals." ScienceDaily. ScienceDaily, 8 July 2012. <www.sciencedaily.com/releases/2012/07/120708162246.htm>.
Washington University in St. Louis. (2012, July 8). Urinary infections steal from hosts' defense arsenals. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2012/07/120708162246.htm
Washington University in St. Louis. "Urinary infections steal from hosts' defense arsenals." ScienceDaily. www.sciencedaily.com/releases/2012/07/120708162246.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins